Key result
Non-ST elevation acute coronary syndromes were associated with lower PAF EC50 values compared to healthy controls, yielding 91.2% sensitivity and 90.0% specificity.
Why the study?
Does ex vivo platelet aggregatory response to platelet activating factor (PAF) differ between patients with non-ST elevation acute coronary syndromes and healthy volunteers?
Case-Control (n=52)
Does ex vivo platelet aggregatory response to platelet activating factor (PAF) differ between patients with non-ST elevation acute coronary syndromes and healthy volunteers?
Answers are grounded in this paper and cite their sources.
Platelet hyperaggregability to PAF is significantly increased in patients with non-ST elevation acute coronary syndromes, suggesting it may contribute to the pathophysiology of ACS.
It is known that myocardial ischaemia increases platelet aggregatory response to various agonists, ex vivo. We investigated the platelet aggregatory response to platelet activating factor (PAF), ex vivo, in patients with non-ST elevation acute coronary syndromes and determined the specificity and sensitivity of this response. Thirty-two consecutive patients with non-ST elevation acute coronary syndromes and 20 healthy volunteers were studied. Platelet aggregation in platelet-rich plasma was studied on the day of admission. The maximal aggregation achieved within 2 min after the addition of PAF (100 nM) was expressed as a percentage of 100% light transmission. PAF EC50 values were defined as the concentration that induces 50% of maximal aggregation. The PAF EC50 values of the non-ST elevation acute coronary syndromes patients were significantly lower compared to those of the controls (p < 0.0001). The maximal percentage of aggregation was also significantly higher (p < 0.0005). Ninety-one per cent of the patients were correctly classified using PAF EC50 values (specificity 90.0% and sensitivity 91.2%); the corresponding results using the maximal percentage of aggregation were 80% (specificity 70.0% and sensitivity 87.5%). The estimated values used as thresholds were 22.47 nM and 17.97 for the PAF EC50 and the maximal percentage of aggregation, respectively. The results of the present study suggest that platelet hyperaggregability to PAF, ex vivo, in non-ST elevation acute coronary syndromes is characterised by a high specificity and sensitivity, and thus it may represent a mechanism contributing to the pathophysiology of acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Michalis et al. (2002) conducted a case-control in Non-ST elevation acute coronary syndromes (n=52). Non-ST elevation acute coronary syndromes vs. Healthy volunteers was evaluated on PAF EC50 values (concentration inducing 50% of maximal aggregation) (p=< 0.0001). Non-ST elevation acute coronary syndromes were associated with lower PAF EC50 values compared to healthy controls, yielding 91.2% sensitivity and 90.0% specificity.
Synapse has enriched 10 related papers. Consider them for comparative context: